These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 29770749)

  • 1. Rosuvastatin and atorvastatin preserve renal function in HIV-1-infected patients with chronic kidney disease and hyperlipidaemia.
    Calza L; Colangeli V; Borderi M; Manfredi R; Marconi L; Bon I; Re MC; Viale P
    HIV Clin Trials; 2018 Jun; 19(3):120-128. PubMed ID: 29770749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
    Calza L; Magistrelli E; Colangeli V; Borderi M; Bussini L; Bon I; Re MC; Viale P
    Infect Dis (Lond); 2017 Oct; 49(10):737-747. PubMed ID: 28683645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression of Renal Impairment and Chronic Kidney Disease in Chronic Heart Failure: An Analysis From GISSI-HF.
    Damman K; Masson S; Lucci D; Gorini M; Urso R; Maggioni AP; Tavazzi L; Tarantini L; Tognoni G; Voors A; Latini R
    J Card Fail; 2017 Jan; 23(1):2-9. PubMed ID: 27638233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin.
    Kroonen MYAM; Stevens J; de Zeeuw D; Heerspink HJL
    Diabetes Obes Metab; 2019 Dec; 21(12):2635-2642. PubMed ID: 31414562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial.
    Kimura G; Kasahara M; Ueshima K; Tanaka S; Yasuno S; Fujimoto A; Sato T; Imamoto M; Kosugi S; Nakao K
    Clin Exp Nephrol; 2017 Jun; 21(3):417-424. PubMed ID: 27392909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
    Vidt DG; Ridker PM; Monyak JT; Schreiber MJ; Cressman MD
    Clin Ther; 2011 Jun; 33(6):717-25. PubMed ID: 21704236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials.
    Idzerda NMA; Pena MJ; Parving HH; de Zeeuw D; Heerspink HJL
    Nephrol Dial Transplant; 2019 Oct; 34(10):1699-1706. PubMed ID: 30184238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease.
    Shepherd J; Kastelein JP; Bittner VA; Carmena R; Deedwania PC; Breazna A; Dobson S; Wilson DJ; Zuckerman AL; Wenger NK;
    Mayo Clin Proc; 2008 Aug; 83(8):870-9. PubMed ID: 18674471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of atorvastatin and rosuvastatin on exercise tolerance in patients with coronary heart disease.
    Liu D; Shen T; Ren C; Xu S; Zhou L; Bai J; Li N; Zhao W; Gao W
    Expert Opin Drug Saf; 2020 Sep; 19(9):1203-1208. PubMed ID: 32571108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes.
    Han E; Kim G; Lee JY; Lee YH; Kim BS; Lee BW; Cha BS; Kang ES
    Endocrinol Metab (Seoul); 2017 Jun; 32(2):274-280. PubMed ID: 28685516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation of renal function by CKD-EPI versus MDRD in a cohort of HIV-infected patients: a cross-sectional analysis.
    Cristelli MP; Cofán F; Rico N; Trullàs JC; Manzardo C; Agüero F; Bedini JL; Moreno A; Oppenheimer F; Miro JM;
    BMC Nephrol; 2017 Feb; 18(1):58. PubMed ID: 28183270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
    Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
    J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Close Monitoring of eGFR Should Be Performed in HIV-Infected Patients Aged over 37 Years.
    Limkunakul C; Srinithiwat P; Lochinda B; Sawanyawisuth K
    Jpn J Infect Dis; 2017 Nov; 70(6):656-659. PubMed ID: 28890502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy.
    Rossi C; Raboud J; Walmsley S; Cooper C; Antoniou T; Burchell AN; Hull M; Chia J; Hogg RS; Moodie EE; Klein MB;
    BMC Infect Dis; 2017 Apr; 17(1):246. PubMed ID: 28376824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased non-HDL-C level linked with a rapid rate of renal function decline in HIV-infected patients.
    Hara M; Yanagisawa N; Ohta A; Momoki K; Tsuchiya K; Nitta K; Ando M
    Clin Exp Nephrol; 2017 Apr; 21(2):275-282. PubMed ID: 27194410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between uric acid levels and renal function of CKD patients with hyperlipidemia: a sub-analysis of the ASUCA trial.
    Kuwabara Y; Yasuno S; Kasahara M; Ueshima K; Nakao K
    Clin Exp Nephrol; 2020 May; 24(5):420-426. PubMed ID: 31875936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and risk factors for chronic kidney disease among HIV-infected antiretroviral therapy-naïve patients in mainland China: a multicenter cross-sectional study.
    Cao Y; Gong M; Han Y; Xie J; Li X; Zhang L; Li Y; Song X; Zhu T; Li T
    Nephrology (Carlton); 2013 Apr; 18(4):307-12. PubMed ID: 23311442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?
    Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
    Expert Opin Pharmacother; 2015; 16(10):1449-61. PubMed ID: 26037614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1).
    Rutter MK; Prais HR; Charlton-Menys V; Gittins M; Roberts C; Davies RR; Moorhouse A; Jinadev P; France M; Wiles PG; Gibson JM; Dean J; Kalra PA; Cruickshank JK; Durrington PN
    Diabet Med; 2011 Jan; 28(1):100-8. PubMed ID: 21166851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Atorvastatin Dose and Concomitant Use of Angiotensin-Converting Enzyme Inhibitors on Renal Function Changes over Time in Patients with Stable Coronary Artery Disease: A Prospective Observational Study.
    Wieczorek-Surdacka E; Świerszcz J; Surdacki A
    Int J Mol Sci; 2016 Feb; 17(2):. PubMed ID: 26848655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.